Literature DB >> 32714520

Management of Direct-Acting Antiviral Failures.

Maryam Alimirah1, Omar Sadiq2, Stuart C Gordon2,3.   

Abstract

Answer questions and earn CME.
© 2020 by the American Association for the Study of Liver Diseases.

Year:  2020        PMID： 32714520      PMCID： PMC7373768          DOI： 10.1002/cld.956

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  7 in total

1.  Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.

Authors:  David Wyles; Ola Weiland; Betty Yao; Frank Weilert; Jean-Francois Dufour; Stuart C Gordon; Albrecht Stoehr; Ashley Brown; Stefan Mauss; Zhenzhen Zhang; Tami Pilot-Matias; Lino Rodrigues; Federico J Mensa; Fred Poordad
Journal:  J Hepatol       Date:  2019-03-08       Impact factor: 25.083

2.  Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.

Authors:  Mei Lu; Kuan-Han Wu; Jia Li; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Loralee B Rupp; Talan Zhang; Sheri Trudeau; Stuart C Gordon
Journal:  J Viral Hepat       Date:  2019-07-04       Impact factor: 3.728

3.  Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.

Authors:  Brian Pearlman; Michael Perrys; Andrew Hinds
Journal:  Am J Gastroenterol       Date:  2019-09       Impact factor: 10.864

Review 4.  Protective immunity against hepatitis C: many shades of gray.

Authors:  Mohamed S Abdel-Hakeem; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2014-06-16       Impact factor: 7.561

5.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Authors:  Marc Bourlière; Stuart C Gordon; Steven L Flamm; Curtis L Cooper; Alnoor Ramji; Myron Tong; Natarajan Ravendhran; John M Vierling; Tram T Tran; Stephen Pianko; Meena B Bansal; Victor de Lédinghen; Robert H Hyland; Luisa M Stamm; Hadas Dvory-Sobol; Evguenia Svarovskaia; Jie Zhang; K C Huang; G Mani Subramanian; Diana M Brainard; John G McHutchison; Elizabeth C Verna; Peter Buggisch; Charles S Landis; Ziad H Younes; Michael P Curry; Simone I Strasser; Eugene R Schiff; K Rajender Reddy; Michael P Manns; Kris V Kowdley; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

6.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

Review 7.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.